Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (307)	8/7/2003 1:05:19 PM
From: Icebrg	Read Replies (1) of 824

>>Why bother if < 6mos?>> The problem is that Alexion has not been able to "show" that there is a survival benefit / reduction in infarcts at 30 days for the population they set out to prove this for. Now, if they can show this type of benefits at 180 days instead, I actually think it is a more impressive feat, as it would indicate that the effect is lasting and this should warrant an approval. If they have not been able to show the benefits at either 30 or 180 days, I think their case is much more doubtful. It is of course difficult to judge this matter, as we don't have any details. We don't know how close they were. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next